On October 21, 2026, JYMed Peptide joined the Peptide Drug Hunting Consortium (PDHC) to host an international webinar exploring modern approaches to more efficient, scalable, and sustainable peptide manufacturing. The session brought together industry professionals...
JYMed Peptide | October 9, 2026 Three fast-paced days at CPHI Milan 2026 have come to an end, bringing together pharmaceutical companies, manufacturers, and industry professionals from across the global supply chain. From October 6–8, JYMed Peptide welcomed clients,...
On the occasion of the 77th anniversary of the founding of the People's Republic of China, JYMed Peptide extends its warmest wishes to our clients, partners, and friends around the world. May you enjoy a joyful holiday, good health, and continued success. Red flags...
How can modern synthesis strategies help make peptide production more efficient, scalable, and sustainable? On October 21, 2026, JYMed Peptide will join PDHC Spotlight Live for “From Sequence to Scalable Supply: Modern Strategies for Efficient and Greener Peptide...
As the Mid-Autumn Festival approaches, JYMed Peptide extends its warmest wishes to our clients, partners, and friends around the world. May the full moon bring you reunion, joy, and every happiness with your loved ones. A full moon lights up homes across the world. A...
From September 6 to 11, 2026, the European Peptide Symposium (EPS 2026) brought together leading scientists, researchers, and industry professionals at the University of Vienna in Austria. As one of Europe’s leading scientific gatherings for peptide research, the...
JYMed Peptide is pleased to announce that Hubei JXBio Pharmaceutical Co., Ltd, its peptide API manufacturing site, has received Korean Drug Master File (K-DMF) registration for Teriparatide Acetate from South Korea’s Ministry of Food and Drug Safety (MFDS). The...
To All Our Customers, Partners, and Members of the Public: We have recently become aware of fraudulent websites impersonating our company online. These fake websites have been unlawfully copying our corporate information, business descriptions, and other materials and...
Against the backdrop of sustained growth in the global peptide drug industry, and steadily increasing global client demand for GLP-1-class peptides, peptide-drug conjugates (PDCs), peptide CDMO services, and related capabilities, JYMed Peptides (hereinafter referred...
中文